Medtide Inc
03880
Company Profile
Business description
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
Contact
No. 69, 12 Street
Qiantang District
Zhejiang
Hangzhou
CHNT: +86 57186803880
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
566
Stocks News & Analysis
stocks
Higher fair value for undervalued wide moat share
Investors are overly concerned with upcoming capital expenditures.
stocks
Fears of deteriorating loan quality sends bank share plummeting
We maintain our fair value estimate despite unfavourable economic conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,026.90 | 46.30 | 0.52% |
| CAC 40 | 8,375.70 | 9.17 | -0.11% |
| DAX 40 | 24,636.16 | 35.06 | -0.14% |
| Dow JONES (US) | 52,112.91 | 236.80 | 0.46% |
| FTSE 100 | 10,501.55 | 6.47 | -0.06% |
| HKSE | 23,026.68 | 354.82 | 1.57% |
| NASDAQ | 25,630.35 | 332.73 | 1.32% |
| Nikkei 225 | 69,468.11 | 107.23 | 0.15% |
| NZX 50 Index | 13,545.56 | 50.32 | 0.37% |
| S&P 500 | 7,407.86 | 53.84 | 0.73% |
| S&P/ASX 200 | 8,823.40 | 46.50 | 0.53% |
| SSE Composite Index | 4,073.90 | 46.64 | 1.16% |